Covid 19: A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Oberver-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine

Grants and Contracts Details

StatusActive
Effective start/end date6/16/211/7/24

Funding

  • PPD Investigator Services LLC: $1,819,704.00